Pretzel Therapeutics is a clinical-stage biotech company developing small molecule therapies that target mitochondrial biology to treat metabolic diseases, rare mitochondrial disorders, and aging-related conditions. The company's lead program PX578 entered Phase 1 clinical trials in 2025, targeting POLRMT as a novel mechanism for metabolic disease treatment. Pretzel collaborates with leading research institutions including SciLifeLab to advance mitochondrial drug discovery.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2024
Sep 2022
Create a free account to see which investors have funded this company.
Create Free Account
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
